BACKGROUND: Congenital hyperinsulinism (CHI) is a cause of persistent hypoglycemia due to unregulated insulin secretion from pancreatic β-cells. Histologically, there are two major subgroups, focal and diffuse. Focal CHI is typically unresponsive to diazoxide and can be cured with surgical removal of the focal lesion. AIMS: We report on three patients with focal CHI to illustrate the marked clinical, genetic, radiological, and histological heterogeneity. METHODS AND RESULTS: The first two patients had focal CHI due to a paternal (c.3992-9G→A) ABCC8 mutation. One of these patients was fully responsive to a small dose (5 mg/kg · d) of diazoxide, whereas the other patient was medically unresponsive. In both patients, the focal lesions were accurately localized preoperatively by [(18)F]dihydroxyphenylalanine (DOPA) positron emission tomography (PET) and surgically resected. The third patient had a paternally inherited ABCC8 (A1493T) mutation, and the initial [(18)F]DOPA PET scan indicated extensive uptake of DOPA in the body and tail of the pancreas. However, despite surgical resection of the body and tail, this patient continued to have severe CHI. A subsequent [(18)F]DOPA PET scan now showed markedly increased DOPA uptake in the remaining body and head of the pancreas. This focal lesion occupied virtually the whole of the pancreas. conclusions: These three cases illustrate that focal lesions even with the same genotype (c.3992-9G→A) may have a different clinical presentation and that [(18)F]DOPA PET scans in very large focal lesions may be difficult to interpret.
BACKGROUND: Congenital hyperinsulinism (CHI) is a cause of persistent hypoglycemia due to unregulated insulin secretion from pancreatic β-cells. Histologically, there are two major subgroups, focal and diffuse. Focal CHI is typically unresponsive to diazoxide and can be cured with surgical removal of the focal lesion. AIMS: We report on three patients with focal CHI to illustrate the marked clinical, genetic, radiological, and histological heterogeneity. METHODS AND RESULTS: The first two patients had focal CHI due to a paternal (c.3992-9G→A) ABCC8 mutation. One of these patients was fully responsive to a small dose (5 mg/kg · d) of diazoxide, whereas the other patient was medically unresponsive. In both patients, the focal lesions were accurately localized preoperatively by [(18)F]dihydroxyphenylalanine (DOPA) positron emission tomography (PET) and surgically resected. The third patient had a paternally inherited ABCC8 (A1493T) mutation, and the initial [(18)F]DOPA PET scan indicated extensive uptake of DOPA in the body and tail of the pancreas. However, despite surgical resection of the body and tail, this patient continued to have severe CHI. A subsequent [(18)F]DOPA PET scan now showed markedly increased DOPA uptake in the remaining body and head of the pancreas. This focal lesion occupied virtually the whole of the pancreas. conclusions: These three cases illustrate that focal lesions even with the same genotype (c.3992-9G→A) may have a different clinical presentation and that [(18)F]DOPA PET scans in very large focal lesions may be difficult to interpret.
Authors: K Mohnike; O Blankenstein; H T Christesen; J De Lonlay; K Hussain; K P Koopmans; H Minn; W Mohnike; A Mutair; T Otonkoski; J Rahier; M Ribeiro; E Schoenle; C N Fékété Journal: Horm Res Date: 2006-05-19
Authors: S A Kassem; I Ariel; P S Thornton; K Hussain; V Smith; K J Lindley; A Aynsley-Green; B Glaser Journal: Diabetes Date: 2001-12 Impact factor: 9.461
Authors: Mariko Suchi; Courtney M MacMullen; Paul S Thornton; N Scott Adzick; Arupa Ganguly; Eduardo D Ruchelli; Charles A Stanley Journal: Mod Pathol Date: 2006-01 Impact factor: 7.842
Authors: Timo Otonkoski; Kirsti Näntö-Salonen; Marko Seppänen; Riitta Veijola; Hanna Huopio; Khalid Hussain; Päivi Tapanainen; Olli Eskola; Riitta Parkkola; Klas Ekström; Yves Guiot; Jacques Rahier; Markku Laakso; Risto Rintala; Pirjo Nuutila; Heikki Minn Journal: Diabetes Date: 2006-01 Impact factor: 9.461
Authors: Anthony Raffo; Kolbe Hancock; Teresa Polito; Yuli Xie; Gordon Andan; Piotr Witkowski; Mark Hardy; Pasquale Barba; Caterina Ferrara; Antonella Maffei; Matthew Freeby; Robin Goland; Rudolph L Leibel; Ian R Sweet; Paul E Harris Journal: J Endocrinol Date: 2008-07 Impact factor: 4.286
Authors: Pablo Laje; Lisa J States; Hongming Zhuang; Susan A Becker; Andrew A Palladino; Charles A Stanley; N Scott Adzick Journal: J Pediatr Surg Date: 2013-02 Impact factor: 2.545
Authors: Milena Pizzoferro; Gabriele Masselli; Arianna Maiorana; Emanuele Casciani; Saadi Sollaku; Carlo Dionisi-Vici; Marco Spada; Claudio Altini; Maria Felicia Villani; Vittoria Rufini; Gianfranco Gualdi; Maria Carmen Garganese Journal: Am J Nucl Med Mol Imaging Date: 2022-04-15
Authors: Julie Bendix; Mette G Laursen; Michael B Mortensen; Maria Melikian; Evgenia Globa; Sönke Detlefsen; Lars Rasmussen; Henrik Petersen; Klaus Brusgaard; Henrik T Christesen Journal: Front Endocrinol (Lausanne) Date: 2018-08-22 Impact factor: 5.555
Authors: Elisa De Franco; Cécile Saint-Martin; Klaus Brusgaard; Amy E Knight Johnson; Lydia Aguilar-Bryan; Pamela Bowman; Jean-Baptiste Arnoux; Annette Rønholt Larsen; May Sanyoura; Siri Atma W Greeley; Raúl Calzada-León; Bradley Harman; Jayne A L Houghton; Elisa Nishimura-Meguro; Thomas W Laver; Sian Ellard; Daniela Del Gaudio; Henrik Thybo Christesen; Christine Bellanné-Chantelot; Sarah E Flanagan Journal: Hum Mutat Date: 2020-02-17 Impact factor: 4.878
Authors: Ross J Craigie; Maria Salomon-Estebanez; Daphne Yau; Bing Han; Walaa Mal; Melanie Newbould; Edmund Cheesman; Stefania Bitetti; Zainab Mohamed; Rakesh Sajjan; Raja Padidela; Mars Skae; Sarah Flanagan; Sian Ellard; Karen E Cosgrove; Indraneel Banerjee; Mark J Dunne Journal: Front Endocrinol (Lausanne) Date: 2018-10-17 Impact factor: 5.555